Karen Silence

Zwijnaarde, VLG 9052, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome.

ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome.

Journal: Science translational medicine

Published: September 18, 2024

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis.

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: September 17, 2024

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.

Journal: iScience

Published: July 25, 2024

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK.

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK.

Journal: Scientific reports

Published: January 20, 2023

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.

Journal: Cancer

Published: June 01, 2021

Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.

Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: December 18, 2020

ARGX-117, a therapeutic complement inhibiting antibody targeting C2.

ARGX-117, a therapeutic complement inhibiting antibody targeting C2.

Journal: The Journal of allergy and clinical immunology

Published: February 27, 2020

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.

Journal: Frontiers in immunology

Published: April 27, 2017

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 02, 2017

CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.

CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.

Journal: Histopathology

Published: March 01, 2017

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Journal: Oncotarget

Published: February 15, 2017

CD70: An emerging target in cancer immunotherapy.

CD70: An emerging target in cancer immunotherapy.

Journal: Pharmacology & therapeutics

Published: May 28, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026